AFYREN's Industrial Ascent
AFYREN Reports €1 Million Sales Increase in H1 2026, Plans Further Production Boosts
Anonymous
French greentech company AFYREN has matched its entire 2025 revenue in just six months. The company reported €1 million in sales for the first half of 2026 — doubling the pace of its previous year — as its AFYREN NEOXY biorefinery in northern France picks up speed, according to Business Wire.
CEO Nicolas Sordet said the company is "producing, shipping and invoicing at an increasing pace." But he was quick to add that "the plant is still far from reaching its full potential." A planned technical shutdown in June is expected to unlock faster output in the second half of 2026.
H1 Revenue Doubles but Plant Runs at Just 20% Capacity
The NEOXY plant in Carling-Saint-Avold is currently running at roughly 20% of its full production capacity — about 3,200 tonnes out of a 16,000-tonne annual target, according to Business Wire. That gap explains why €1 million in half-year revenue still looks modest for a company with a market cap of around $105 million.
Analysts at firms like Oddo BHF and Portzamparc are watching the ramp-up closely. Some have trimmed their price targets — from around €5.00 to roughly €4.35 — as the timeline for hitting full capacity stretches longer than initially hoped, according to Simply Wall St.
June Shutdown Is a Fix, Not a Failure, Experts Say
The scheduled June 2026 technical shutdown is designed to improve process reliability and push output higher. Industrial experts say this kind of pause is standard for bio-fermentation plants. There is a key difference between "continuous production" — keeping the process running — and "full capacity" — maximizing volume. AFYREN has achieved the first. The second is the goal for H2 2026, according to Yahoo Finance.
The company converts sugar beet co-products into bio-based carboxylic acids. These acids go into flavors, fragrances, animal feed, and lubricants — products traditionally made from petrochemicals. AFYREN claims its process cuts the carbon footprint of these ingredients by up to 81%.
€10 Million in Fresh Funding Backs the Push Forward
AFYREN has secured €10 million in new funding so far in 2026. In February, it raised €7 million through a share capital increase. In April, it received a €3 million grant from the Grand Est Region, funded through the European Just Transition Fund, according to EQS News.
In March 2026, AFYREN also bought out the 49% stake in NEOXY previously held by Bpifrance's SPI fund, giving it full 100% ownership of the plant, according to Morningstar. That move simplifies its finances and means AFYREN will keep all profits once the plant breaks even — a target the company says is just "a few quarters" away.
€165 Million Backlog Points to a Bigger Prize Ahead
Despite the slow ramp-up, demand for AFYREN's products is not the problem. The company holds €165 million in secured, multi-year contracts, according to World Bio Market Insights. That backlog shows manufacturers are ready to buy — as soon as the plant can produce enough to fill orders.
Success at NEOXY is the green light for a second plant. AFYREN is targeting an investment decision for "Plant 2" in 2028, with commissioning set for 2030. The company also has an ongoing project in Thailand with a major sugar producer, using the same "plug-and-play" model to deploy the technology near local biomass sources, according to Business Wire.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
4
Articles
4
Reach
4
A
AnonymousAuthor
